These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 30716469)
21. Chronic exposure to cannabinoids before an emotional trauma may have negative effects on emotional function. Sbarski B; Akirav I Eur Neuropsychopharmacol; 2018 Aug; 28(8):955-969. PubMed ID: 30026011 [TBL] [Abstract][Full Text] [Related]
22. Pilocarpine-induced epileptogenesis in the rat: impact of initial duration of status epilepticus on electrophysiological and neuropathological alterations. Klitgaard H; Matagne A; Vanneste-Goemaere J; Margineanu DG Epilepsy Res; 2002 Sep; 51(1-2):93-107. PubMed ID: 12350385 [TBL] [Abstract][Full Text] [Related]
23. Bidirectional alterations of hippocampal cannabinoid 1 receptors and their endogenous ligands in a rat model of alcohol withdrawal and dependence. Mitrirattanakul S; López-Valdés HE; Liang J; Matsuka Y; Mackie K; Faull KF; Spigelman I Alcohol Clin Exp Res; 2007 May; 31(5):855-67. PubMed ID: 17386072 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors. Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of protective effects of non-selective cannabinoid receptor agonist WIN 55,212-2 against the nitroglycerine-induced acute and chronic animal models of migraine: A mechanistic study. Mohammadi Vosough E; Baradaran Rahimi V; Masoud SA; Mirkarimi HR; Demneh MK; Abed A; Banafshe HR; Askari VR Life Sci; 2019 Sep; 232():116670. PubMed ID: 31330139 [TBL] [Abstract][Full Text] [Related]
27. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Guo J; Ikeda SR Mol Pharmacol; 2004 Mar; 65(3):665-74. PubMed ID: 14978245 [TBL] [Abstract][Full Text] [Related]
28. Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat. Rizzo V; Ferraro G; Carletti F; Lonobile G; Cannizzaro C; Sardo P Neurosci Lett; 2009 Sep; 462(2):135-9. PubMed ID: 19595742 [TBL] [Abstract][Full Text] [Related]
29. Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor distribution and G-protein activation in the 3D reconstructed epileptic rat brain. Sayers KW; Nguyen PT; Blair RE; Sim-Selley LJ; DeLorenzo RJ Epilepsia; 2012 May; 53(5):897-907. PubMed ID: 22509801 [TBL] [Abstract][Full Text] [Related]
30. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Moranta D; Esteban S; García-Sevilla JA Naunyn Schmiedebergs Arch Pharmacol; 2004 May; 369(5):516-24. PubMed ID: 15064921 [TBL] [Abstract][Full Text] [Related]
31. Development of pharmacoresistance to benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status epilepticus. Deshpande LS; Blair RE; Nagarkatti N; Sombati S; Martin BR; DeLorenzo RJ Exp Neurol; 2007 Apr; 204(2):705-13. PubMed ID: 17289026 [TBL] [Abstract][Full Text] [Related]
32. Two distinct classes of muscarinic action on hippocampal inhibitory synapses: M2-mediated direct suppression and M1/M3-mediated indirect suppression through endocannabinoid signalling. Fukudome Y; Ohno-Shosaku T; Matsui M; Omori Y; Fukaya M; Tsubokawa H; Taketo MM; Watanabe M; Manabe T; Kano M Eur J Neurosci; 2004 May; 19(10):2682-92. PubMed ID: 15147302 [TBL] [Abstract][Full Text] [Related]
33. [The synthetic cannabinoid analog WIN 55,212-2 potentiates the amplitudes of glycine-activated currents]. Iatsenko NM; Tsintsadze TSh; Lozova NO Fiziol Zh (1994); 2007; 53(3):31-7. PubMed ID: 17725041 [TBL] [Abstract][Full Text] [Related]
34. Involvement of the CB Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186 [TBL] [Abstract][Full Text] [Related]
35. Non-Status Epilepticus female rats show seizure-like behaviors in the chronic phase of Pilocarpine experimental model. Dal Pai J; da Silva JC; Sanabria V; Amorim RP; Predebon G; Cossa AC; Trindade-Filho E; Amado D Braz J Biol; 2022; 83():e237412. PubMed ID: 35081234 [TBL] [Abstract][Full Text] [Related]
37. Differential neuroprotective effects of the NMDA receptor-associated glycine site partial agonists 1-aminocyclopropanecarboxylic acid (ACPC) and D-cycloserine in lithium-pilocarpine status epilepticus. Peterson SL; Purvis RS; Griffith JW Neurotoxicology; 2004 Sep; 25(5):835-47. PubMed ID: 15288514 [TBL] [Abstract][Full Text] [Related]
38. Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats. del Carmen García M; Adler-Graschinsky E; Celuch SM Naunyn Schmiedebergs Arch Pharmacol; 2003 Oct; 368(4):270-6. PubMed ID: 14504685 [TBL] [Abstract][Full Text] [Related]
39. Topical cannabinoid agonist, WIN55,212-2, reduces cornea-evoked trigeminal brainstem activity in the rat. Bereiter DA; Bereiter DF; Hirata H Pain; 2002 Oct; 99(3):547-556. PubMed ID: 12406531 [TBL] [Abstract][Full Text] [Related]
40. The cannabinoid WIN 55,212-2-mediated protection of dentate gyrus granule cells is driven by CB1 receptors and modulated by TRPA1 and Cav 2.2 channels. Koch M; Kreutz S; Böttger C; Grabiec U; Ghadban C; Korf HW; Dehghani F Hippocampus; 2011 May; 21(5):554-64. PubMed ID: 20135626 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]